Pegylated kynureninase enzymes and uses thereof for the treatment of cancer
AssigneeBoard of Regents, The University of Texas System
InventorsJames Nolan, Michelle Zhang, George Georgiou, Everett Stone, John Blazeck, Christos Karamitros
Life of this patent
Estimating the term…
Abstract
Kynureninase enzymes covalently bound to polyethylene glycol are described. Aspects of the disclosure provide compositions and methods for improving the effective treatment of cancer by way of kynurenine depletion using such molecules.
Claims10
A kynureninase homodimer covalently bound to one or more polyethylene glycol (PEG) molecules, wherein the ratio of PEG molecules to homodimer is from 15:1 to 30:1, wherein the homodimer comprises two polypeptide monomers each having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:
- 1, wherein each polypeptide monomer comprises the substitutions L72N, H102W, A282P, F306W, S408N, A436T, and N333T relative to SEQ ID NO:
- 1.
A kynureninase homodimer produced by a method comprising contacting the homodimer with a PEGylation agent, wherein the molar input of PEGylation agent to homodimer is from about 15:1 to 30:1, wherein the homodimer comprises two polypeptide monomers each having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:
- 1, wherein each polypeptide monomer comprises the substitutions L72N, H102W, A282P, F306W, S408N, A436T, and N333T relative to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.